No obvious extra cardiovascular risk associated with low-dose NSAIDs

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 6, 2009, Pages 600-601

  Moore, N ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANALYTICAL ERROR; CARDIOVASCULAR RISK; DEATH; HEART INFARCTION; HUMAN; LETTER; LOW DRUG DOSE; MORTALITY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION;

AGE FACTORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CAUSE OF DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; MYOCARDIAL INFARCTION; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS;

EID: 70450241064     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.66     Document Type: Letter

References (5)

1. Fosbøl, E.L. et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin. Pharmacol. Ther. 85, 190-197 (2009).
2. Fosbøl, E.L. et al. The pattern of use of non-steroidal anti-infammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidemiol. Drug Saf. 17, 822-833 (2008).
3. Suissa, S. Efectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am. J. Respir. Crit. Care Med. 168, 49-53 (2003).
4. Maclure, M. The case-crossover design: a method for studying transient efects on the risk of acute events. Am. J. Epidemiol. 133, 144-153 (1991).
5. van Staa, T.P., Rietbrock, S., Setakis, E. & Leufkens, H.G. Does the varied use of NSAIDs explain the diferences in the risk of myocardial infarction? J. Intern. Med. 264, 481-492 (2008).